13 WTHR - Indianapolis News |FDA extends review of XenoPort-Glaxo pain drug

FDA extends review of XenoPort-Glaxo pain drug

Posted: Updated:

NEW YORK (AP) - The Food and Drug Administration needs three more months to review an application to a neuropathic pain drug being developed by XenoPort Inc. and GlaxoSmithKline PLC, the companies said.

XenoPort and GlaxoSmithKline said late Friday the FDA should complete its review of the drug, called gabapentin enacarbil, by Feb. 9, 2010. The review period was scheduled to end Monday. The FDA wanted the companies to develop a strategy to evaluate the drug's risks, and after GlaxoSmithKline submitted that strategy, the agency needed additional time to review it.

XenoPort is based in Santa Clara, Calif., and GlaxoSmithKline is headquartered in London. In premarket trading, XenoPort stock rose 7 cents to $18.21 from $18.14.

Copyright 2009 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Powered by WorldNow
All content © Copyright 2002 - 2010 WorldNow and WTHR. All Rights Reserved.
For more information on this site, please read our Privacy Policy and Terms of Service.It is the policy of The Dispatch Broadcast Group to provide equal employment opportunity to all qualified individuals without regard to their race, color, religion, national origin, age, sex, marital status, disability, military status, citizenship or any other legally-protected status in accordance with applicable local, state and federal law. Jobs at WTHR EEO Public File Report